Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry
Cross-sectional tumor measures are traditional clinical trial endpoints; however volumetric measures may better assess tumor growth. We determined the correlation and compared the prognostic impact of cross-sectional and volumetric measures of progressive disease (PD) among patients with DIPG. Imagi...
Uloženo v:
| Vydáno v: | Neuro-oncology (Charlottesville, Va.) Ročník 24; číslo 9; s. 1598 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
01.09.2022
|
| Témata: | |
| ISSN: | 1523-5866, 1523-5866 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Cross-sectional tumor measures are traditional clinical trial endpoints; however volumetric measures may better assess tumor growth. We determined the correlation and compared the prognostic impact of cross-sectional and volumetric measures of progressive disease (PD) among patients with DIPG.
Imaging and clinical data were abstracted from the International DIPG Registry. Tumor volume and cross-sectional product (CP) were measured with mint Lesion™ software using manual contouring. Correlation between CP and volume (segmented and mathematical [ellipsoid] model) thresholds of PD were assessed by linear regression. Landmark analyses determined differences in survival (via log-rank) between patients classified as PD versus non-PD by CP and volumetric measurements at 1, 3, 5, 7, and 9 months postradiotherapy (RT). Hazard ratios (HR) for survival after these time points were calculated by Cox regression.
A total of 312 MRIs (46 patients) were analyzed. Comparing change from the previous smallest measure, CP increase of 25% (PD) correlated with a segmented volume increase of 30% (R2 = 0.710), rather than 40% (spherical model extrapolation). CP-determined PD predicted survival at 1 month post-RT (HR = 2.77), but not other time points. Segmented volumetric-determined PD (40% threshold) predicted survival at all imaging timepoints (HRs = 2.57, 2.62, 3.35, 2.71, 16.29), and 30% volumetric PD threshold predicted survival at 1, 3, 5, and 9 month timepoints (HRs = 2.57, 2.62, 4.65, 5.54). Compared to ellipsoid volume, segmented volume demonstrated superior survival associations.
Segmented volumetric assessments of PD correlated better with survival than CP or ellipsoid volume at most time points. Semiautomated tumor volume likely represents a more accurate, prognostically-relevant measure of disease burden in DIPG. |
|---|---|
| AbstractList | Cross-sectional tumor measures are traditional clinical trial endpoints; however volumetric measures may better assess tumor growth. We determined the correlation and compared the prognostic impact of cross-sectional and volumetric measures of progressive disease (PD) among patients with DIPG.
Imaging and clinical data were abstracted from the International DIPG Registry. Tumor volume and cross-sectional product (CP) were measured with mint Lesion™ software using manual contouring. Correlation between CP and volume (segmented and mathematical [ellipsoid] model) thresholds of PD were assessed by linear regression. Landmark analyses determined differences in survival (via log-rank) between patients classified as PD versus non-PD by CP and volumetric measurements at 1, 3, 5, 7, and 9 months postradiotherapy (RT). Hazard ratios (HR) for survival after these time points were calculated by Cox regression.
A total of 312 MRIs (46 patients) were analyzed. Comparing change from the previous smallest measure, CP increase of 25% (PD) correlated with a segmented volume increase of 30% (R2 = 0.710), rather than 40% (spherical model extrapolation). CP-determined PD predicted survival at 1 month post-RT (HR = 2.77), but not other time points. Segmented volumetric-determined PD (40% threshold) predicted survival at all imaging timepoints (HRs = 2.57, 2.62, 3.35, 2.71, 16.29), and 30% volumetric PD threshold predicted survival at 1, 3, 5, and 9 month timepoints (HRs = 2.57, 2.62, 4.65, 5.54). Compared to ellipsoid volume, segmented volume demonstrated superior survival associations.
Segmented volumetric assessments of PD correlated better with survival than CP or ellipsoid volume at most time points. Semiautomated tumor volume likely represents a more accurate, prognostically-relevant measure of disease burden in DIPG. Cross-sectional tumor measures are traditional clinical trial endpoints; however volumetric measures may better assess tumor growth. We determined the correlation and compared the prognostic impact of cross-sectional and volumetric measures of progressive disease (PD) among patients with DIPG.BACKGROUNDCross-sectional tumor measures are traditional clinical trial endpoints; however volumetric measures may better assess tumor growth. We determined the correlation and compared the prognostic impact of cross-sectional and volumetric measures of progressive disease (PD) among patients with DIPG.Imaging and clinical data were abstracted from the International DIPG Registry. Tumor volume and cross-sectional product (CP) were measured with mint Lesion™ software using manual contouring. Correlation between CP and volume (segmented and mathematical [ellipsoid] model) thresholds of PD were assessed by linear regression. Landmark analyses determined differences in survival (via log-rank) between patients classified as PD versus non-PD by CP and volumetric measurements at 1, 3, 5, 7, and 9 months postradiotherapy (RT). Hazard ratios (HR) for survival after these time points were calculated by Cox regression.METHODSImaging and clinical data were abstracted from the International DIPG Registry. Tumor volume and cross-sectional product (CP) were measured with mint Lesion™ software using manual contouring. Correlation between CP and volume (segmented and mathematical [ellipsoid] model) thresholds of PD were assessed by linear regression. Landmark analyses determined differences in survival (via log-rank) between patients classified as PD versus non-PD by CP and volumetric measurements at 1, 3, 5, 7, and 9 months postradiotherapy (RT). Hazard ratios (HR) for survival after these time points were calculated by Cox regression.A total of 312 MRIs (46 patients) were analyzed. Comparing change from the previous smallest measure, CP increase of 25% (PD) correlated with a segmented volume increase of 30% (R2 = 0.710), rather than 40% (spherical model extrapolation). CP-determined PD predicted survival at 1 month post-RT (HR = 2.77), but not other time points. Segmented volumetric-determined PD (40% threshold) predicted survival at all imaging timepoints (HRs = 2.57, 2.62, 3.35, 2.71, 16.29), and 30% volumetric PD threshold predicted survival at 1, 3, 5, and 9 month timepoints (HRs = 2.57, 2.62, 4.65, 5.54). Compared to ellipsoid volume, segmented volume demonstrated superior survival associations.RESULTSA total of 312 MRIs (46 patients) were analyzed. Comparing change from the previous smallest measure, CP increase of 25% (PD) correlated with a segmented volume increase of 30% (R2 = 0.710), rather than 40% (spherical model extrapolation). CP-determined PD predicted survival at 1 month post-RT (HR = 2.77), but not other time points. Segmented volumetric-determined PD (40% threshold) predicted survival at all imaging timepoints (HRs = 2.57, 2.62, 3.35, 2.71, 16.29), and 30% volumetric PD threshold predicted survival at 1, 3, 5, and 9 month timepoints (HRs = 2.57, 2.62, 4.65, 5.54). Compared to ellipsoid volume, segmented volume demonstrated superior survival associations.Segmented volumetric assessments of PD correlated better with survival than CP or ellipsoid volume at most time points. Semiautomated tumor volume likely represents a more accurate, prognostically-relevant measure of disease burden in DIPG.CONCLUSIONSSegmented volumetric assessments of PD correlated better with survival than CP or ellipsoid volume at most time points. Semiautomated tumor volume likely represents a more accurate, prognostically-relevant measure of disease burden in DIPG. |
| Author | Hummel, Trent R Leach, James L Lane, Adam Minturn, Jane E Black, Katie Ziegler, David S Chaney, Brooklyn Lazow, Margot A Kilburn, Lindsay Fouladi, Maryam Glod, John W Packer, Roger Nievelstein, Martijn T Leary, Sarah Hoffman, Lindsey M Greiner, Robert J Bandopadhayhay, Pratiti DeWire-Schottmiller, Mariko de Blank, Peter |
| Author_xml | – sequence: 1 givenname: Margot A orcidid: 0000-0003-4362-4270 surname: Lazow fullname: Lazow, Margot A organization: Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA – sequence: 2 givenname: Martijn T surname: Nievelstein fullname: Nievelstein, Martijn T organization: Department of Radiology and Medical Imaging, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA – sequence: 3 givenname: Adam orcidid: 0000-0002-5522-8112 surname: Lane fullname: Lane, Adam organization: Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA – sequence: 4 givenname: Pratiti surname: Bandopadhayhay fullname: Bandopadhayhay, Pratiti organization: Dana Farber Cancer Institute, Harvard Cancer Center, Boston, Massachusetts, USA – sequence: 5 givenname: Mariko surname: DeWire-Schottmiller fullname: DeWire-Schottmiller, Mariko organization: Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA – sequence: 6 givenname: Maryam orcidid: 0000-0002-5693-035X surname: Fouladi fullname: Fouladi, Maryam organization: Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA – sequence: 7 givenname: John W surname: Glod fullname: Glod, John W organization: Cancer for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA – sequence: 8 givenname: Robert J surname: Greiner fullname: Greiner, Robert J organization: Division of Oncology, Penn State Health Children's Hospital, Hershey, Pennsylvania, USA – sequence: 9 givenname: Lindsey M surname: Hoffman fullname: Hoffman, Lindsey M organization: Division of Oncology, Phoenix Children's Hospital, Phoenix, Arizona, USA – sequence: 10 givenname: Trent R surname: Hummel fullname: Hummel, Trent R organization: Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA – sequence: 11 givenname: Lindsay surname: Kilburn fullname: Kilburn, Lindsay organization: Division of Oncology, Children's National Medical Center, Washington, DC, USA – sequence: 12 givenname: Sarah surname: Leary fullname: Leary, Sarah organization: Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, Washington, USA – sequence: 13 givenname: Jane E surname: Minturn fullname: Minturn, Jane E organization: Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA – sequence: 14 givenname: Roger surname: Packer fullname: Packer, Roger organization: Division of Oncology, Children's National Medical Center, Washington, DC, USA – sequence: 15 givenname: David S orcidid: 0000-0001-7451-7916 surname: Ziegler fullname: Ziegler, David S organization: School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia – sequence: 16 givenname: Brooklyn surname: Chaney fullname: Chaney, Brooklyn organization: Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA – sequence: 17 givenname: Katie orcidid: 0000-0002-3269-7303 surname: Black fullname: Black, Katie organization: Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA – sequence: 18 givenname: Peter surname: de Blank fullname: de Blank, Peter organization: Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA – sequence: 19 givenname: James L surname: Leach fullname: Leach, James L organization: Department of Radiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35148393$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1PHDEMhqMKVD6vPVY5cpluJtnMBzfE0u1KoFZV4bryJg6kmnGGJHPg3_BTSctW6sGypfd5bfk9YQcUCBn7VIsvtejVgnAOZBYUwAjVfmDHtZaq0l3THPw3H7GTlH4LIWvd1B_ZkdL1slO9OmavD2GYR8zRG45kp-ApJ-6JW-_cnLCMRaNU5ClQ9oT8cfBhhEtuwjhB9CkQz4GbGFKqEprsA8HAR4Q0R0wcyPIw50JjscSIA_xB_h7JT8g3lDES7G2rzY_1YnW35j_x0accX87YoYMh4fm-n7L7rze_rr9Vt9_Xm-ur28oovcyVlcbovnXClSc72DkDzrbN0ojWqbq2nRUACgB6CyCMQdnttHalbCNbK-Qpu3jfO8XwPGPK29Eng8MAhGFOW9nITva6JFrQz3t03o1ot1P0I8SX7b9U5Rt2pIId |
| CitedBy_id | crossref_primary_10_3390_cancers16081595 crossref_primary_10_1007_s10143_024_02676_7 crossref_primary_10_1093_neuonc_noaf058 crossref_primary_10_1093_nop_npaf015 crossref_primary_10_1007_s10143_024_02435_8 crossref_primary_10_3389_fmed_2023_1071447 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| Copyright_xml | – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/neuonc/noac037 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1523-5866 |
| ExternalDocumentID | 35148393 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .2P .I3 .XZ .ZR 0R~ 123 18M 2WC 36B 4.4 48X 53G 5VS 5WD 70D AABZA AACZT AAJKP AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNHQ ABNKS ABPQP ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACUFI ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AGINJ AGKEF AGQXC AGSYK AGUTN AHMMS AHXPO AIAGR AIJHB AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX AOIJS APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF EMB EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HYE HZ~ IOX J21 JXSIZ KOP KQ8 KSI KSN MHKGH N9A NGC NOMLY NOYVH NPM O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM Q1. Q5Y RD5 ROX RPM RUSNO RW1 RXO SV3 TEORI TJX TR2 W8F WOQ X7H YAYTL YKOAZ YXANX ~91 7X8 AHGBF AJBYB KBUDW |
| ID | FETCH-LOGICAL-c354t-d2cc597f0f0218abfcafd764c07f311d8d0aa3aaa9daa0cce28b55fb55d627d02 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 8 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000784154900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1523-5866 |
| IngestDate | Thu Oct 02 11:38:03 EDT 2025 Thu Apr 03 06:53:57 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | volume three-dimensional (3D) progressive disease cross-product diffuse intrinsic pontine glioma (DIPG) |
| Language | English |
| License | The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c354t-d2cc597f0f0218abfcafd764c07f311d8d0aa3aaa9daa0cce28b55fb55d627d02 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-5693-035X 0000-0002-5522-8112 0000-0003-4362-4270 0000-0002-3269-7303 0000-0001-7451-7916 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/9435485 |
| PMID | 35148393 |
| PQID | 2628295523 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2628295523 pubmed_primary_35148393 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-01 |
| PublicationDateYYYYMMDD | 2022-09-01 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Neuro-oncology (Charlottesville, Va.) |
| PublicationTitleAlternate | Neuro Oncol |
| PublicationYear | 2022 |
| SSID | ssj0021561 |
| Score | 2.4011304 |
| Snippet | Cross-sectional tumor measures are traditional clinical trial endpoints; however volumetric measures may better assess tumor growth. We determined the... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1598 |
| SubjectTerms | Astrocytoma Brain Stem Neoplasms - diagnostic imaging Brain Stem Neoplasms - drug therapy Brain Stem Neoplasms - radiotherapy Cross-Sectional Studies Diffuse Intrinsic Pontine Glioma Glioma - pathology Humans Registries |
| Title | Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35148393 https://www.proquest.com/docview/2628295523 |
| Volume | 24 |
| WOSCitedRecordID | wos000784154900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JSwMxFA5uiBf3pW5E8Do0TWZpvYi4H1qKqPRWXrOUAZvUztTf40_1ZWZa8SAIHmYYmMkkJC9vz_sIOQ-ZNiw0uJESH2bkigW-ClQwgCjhAxTRMi7BJpJOp9nrtbqVwy2r0ipnPLFg1MpJ7yOv89jH_CK0my7H74FHjfLR1QpCY5EsC1RlfEpX0ptHEVCaVfVSuQiiZhzPizaKutVTZ2XdOpBMJL-rl4WYudv47wA3yXqlYNKrkiK2yIK222S1XYXQd8jna8GPfGF-qq0au9TmGU0t9VAp00zjI76zuHh07DyMhKbDt9SN4ILKOWYhzR0t5GuQFalcvsdR6W3MKFhF3TTHrzU2mUxm6Xa-E1Q36Q8nJL157N7Xb9r39EkPC-S5XfJyd_t8_RBUMA2BFFGYB4pLiWaJYcbrCzAwEoxK4lCyxIhGQzUVAxAA0FIATErNm0gEBi8V80QxvkeWrLP6gNAYopaSDYV_E6EBGGgTQogWEYpULVtQI2ezue_jNvCxDbDaTbP-9-zXyH65gP1xWa-j7w8roB4oDv_Q-oiscX_AocgiOybLBpmAPiEr8iNPs8lpQV9473TbXyRb4Rs |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Volumetric+endpoints+in+diffuse+intrinsic+pontine+glioma%3A+comparison+to+cross-sectional+measures+and+outcome+correlations+in+the+International+DIPG%2FDMG+Registry&rft.jtitle=Neuro-oncology+%28Charlottesville%2C+Va.%29&rft.au=Lazow%2C+Margot+A&rft.au=Nievelstein%2C+Martijn+T&rft.au=Lane%2C+Adam&rft.au=Bandopadhayhay%2C+Pratiti&rft.date=2022-09-01&rft.issn=1523-5866&rft.eissn=1523-5866&rft.volume=24&rft.issue=9&rft.spage=1598&rft_id=info:doi/10.1093%2Fneuonc%2Fnoac037&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1523-5866&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1523-5866&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1523-5866&client=summon |